<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56874">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01681433</url>
  </required_header>
  <id_info>
    <org_study_id>GU12-159</org_study_id>
    <nct_id>NCT01681433</nct_id>
  </id_info>
  <brief_title>OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone</brief_title>
  <official_title>The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoosier Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OncoGenex Technologies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Oncology Group</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II study has been designed to evaluate the anti-tumor effects of adding OGX-427
      to continuing abiraterone acetate and prednisone treatment in men with metastatic
      castrate-resistant prostate cancer (MCRPC) who have prostate-specific antigen (PSA)
      progression
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:  This is a multi-center study.

      This is an open-label, randomized, Phase II clinical trial designed to evaluate the
      anti-tumor effects of OGX-427 and continuing abiraterone acetate and prednisone versus
      continuing abiraterone acetate and prednisone alone in men with MCRPC who have evidence of
      PSA progression but no evidence of symptomatic or radiographic progression that would
      require alternative therapy (e.g., needing radiation therapy for pain or significant
      progression of visceral metastases).

      Patients on the control arm will be allowed to cross-over to receive OGX-427 following
      documented disease progression. Patients will be randomized with equal probability to one of
      the following arms:

      EXPERIMENTAL ARM (Arm A):

      OGX-427 Starting within 7 days of randomization, three loading doses of 600 mg intravenously
      (IV) within Week 1 if possible (up to 10 days of initiating treatment), followed by weekly
      doses of 800 mg IV

      Continuation of standard therapy with abiraterone acetate 1000 mg by mouth (PO) daily and
      prednisone 10-20 mg PO daily

      CONTROL ARM (Arm B):

      Continuation of standard therapy with abiraterone acetate 1000 mg PO daily and prednisone
      10-20 mg PO daily

      After documented disease progression, patients on Arm B may opt to receive OGX-427 treatment
      (according to the Arm A schedule) following a screening evaluation (i.e., all inclusion and
      exclusion criteria have been met)

      Both Arms:

      Evaluations at 4 week-intervals. Disease assessments required at the milestone Day 60
      assessment (expected to occur after 8 weeks of treatment and prior to Day 1, Week 9) and at
      16, 24, 32, 40, and 48 weeks (if applicable) or until documented disease progression.
      Patients who are withdrawn from the study for a reason other than documented disease
      progression or patient withdrawal of consent will be followed every 4 weeks in the
      Off-Treatment Follow-up Period until documented disease progression.

      Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

      Life Expectancy: Not Specified

      Hematopoietic:

        -  Absolute neutrophil count (ANC) ≥ 1.5 x 109 cells /L, platelet count ≥ 100 x 109 /L,
           and hemoglobin ≥ 9 g/dL without transfusion

      Hepatic:

        -  Total bilirubin ≤ 1.1 x upper limit of normal (ULN) unless elevated secondary to
           conditions such as Gilbert's disease, in which case a direct bilirubin ≤ ULN is
           required

        -  Serum glutamic pyruvic transaminase (SGPT), alanine transaminase (ALT) and alanine
           transaminase (SGOT) aspartate transaminase (AST) ≤ 3.0 x ULN

      Renal:

        -  Creatinine ≤ 1.3 x ULN

      Cardiac:

        -  Known left ventricular ejection fraction (LVEF) &lt;50% or New York Heart Association
           (NYHA) Functional Classification Class III or IV heart failure

      Other:

        -  Castrate serum testosterone level (&lt; 50 ng/dL or &lt; 1.7 nmol/L)

        -  Potassium within normal limits
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>60 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To ascertain whether Arm A has a greater proportion of patients observed to be alive without progression at Day 60 (±7 days) as compared to Arm B.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA Response</measure>
    <time_frame>60 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare arms to determine the proportion of patients who have a PSA response (≥ 30% decline) and any PSA decline post-randomization</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Objective Response</measure>
    <time_frame>60 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare arms to determine the objective response of study patients.</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>60 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare arms to determine the rates of progression-free survival for study patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>60 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare arms to determine the time to disease progression of study patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Circulating Tumor Cell (CTC) Counts</measure>
    <time_frame>Every 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare arms to determine circulating tumor cell (CTC) counts for patients at baseline and while on study</description>
  </other_outcome>
  <other_outcome>
    <measure>Protein Levels</measure>
    <time_frame>Every 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare arms to determine levels of heat shock protein 27 (Hsp27), clusterin, and other relevant proteins of patients at baseline and during study</description>
  </other_outcome>
  <other_outcome>
    <measure>Phosphatase and tensin homolog (PTEN) Deletion Status</measure>
    <time_frame>Every 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare arms to determine PTEN deletion status in original pathology specimens correlated with clinical outcomes</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Metastatic Castrate-Resistant Prostate Cancer</condition>
  <condition>PSA</condition>
  <arm_group>
    <arm_group_label>Experimental: Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OGX-427 + continuation of standard therapy with abiraterone acetate and prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm: Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuation of standard therapy with abiraterone acetate and prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OGX-427</intervention_name>
    <description>OGX-427 started within 7 days of randomization, three loading doses of 600 mg IV within Week 1 if possible (up to 10 days of initiating treatment), followed by weekly doses of 800 mg IV</description>
    <arm_group_label>Experimental: Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate</intervention_name>
    <description>Standard therapy: Abiraterone Acetate 1000 mg PO daily</description>
    <arm_group_label>Experimental: Arm A</arm_group_label>
    <arm_group_label>Control Arm: Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Standard therapy: Prednisone 10-20 mg PO daily</description>
    <arm_group_label>Experimental: Arm A</arm_group_label>
    <arm_group_label>Control Arm: Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet ALL of the following criteria to be eligible for inclusion into the
        study.

          -  Histological or cytological diagnosis of adenocarcinoma of the prostate

          -  Metastatic disease on chest, abdominal, or pelvic computed tomography (CT) scan
             and/or bone scan

          -  Currently receiving abiraterone acetate and prednisone and meeting the following
             criteria:

               -  Any PSA decline within 12 weeks from initiation of abiraterone acetate

               -  Currently tolerating abiraterone acetate (1000 mg oral daily) and prednisone
                  (10-20 mg oral daily)

               -  PSA progression, defined as an increase in PSA which is ≥25% above the nadir and
                  an absolute value of ≥2 ng/mL, which is confirmed by a second value ≥2 weeks
                  later.

               -  No evidence of symptomatic or radiographic progression that would require
                  alternative therapy (e.g., needing radiation therapy for pain or significant
                  progression of visceral metastases or &gt;33% increase in daily opioid use within 2
                  weeks prior to randomization).

          -  All patients who have not had a surgical orchiectomy must continue treatment with a
             luteinizing hormone-releasing hormone (LHRH) agonist or antagonist to maintain a
             castrate level of testosterone.

          -  Patient must fulfill &quot;Prior Therapy&quot; criteria as follows:

               -  Chemotherapy: no more than 1 prior chemotherapy regimen for castrate-resistant
                  prostate cancer (CRPC) is permitted; a minimum of at least 28 days must have
                  passed since the last dose of chemotherapy.

               -  Hormone therapy: hormonal androgen ablation therapy prior to abiraterone is
                  required.

               -  Experimental therapy: prior non-cytotoxic experimental therapy is permitted
                  provided a minimum of at least 14 days has passed since completing therapy.
                  Prior treatment with enzalutamide (MDV3100) is allowed.

               -  Radiation: prior external beam radiation is permitted provided a minimum of at
                  least 14 days have passed since completing radiotherapy (exception for
                  radiotherapy: at least 7 days since completing a single fraction of ≤800 cGy to
                  a restricted field or limited-field radiotherapy to non-marrow bearing area such
                  as an extremity or orbit) at the time of randomization

          -  Must be willing to use effective contraception throughout study treatment and for 3
             months after completion of study treatment if able to father a child.

          -  Must be willing not to change (add or subtract) bone protecting therapy
             (bisphosphonates and/or denosumab) during the study unless changed for toxicity.

          -  Written informed consent must be obtained prior to any protocol-specific procedures
             being performed.

        Exclusion Criteria:

        Subjects meeting ANY of the following exclusion criteria will NOT be eligible for
        inclusion into the study:

          -  Currently receiving abiraterone acetate in combination with any other anti-cancer
             agent (except prednisone)

          -  Documented brain metastases, or carcinomatous meningitis, treated or untreated (Brain
             imaging for asymptomatic patients is not required.)

          -  Cord compression requiring surgery or radiation therapy while on abiraterone
             treatment

          -  Active second malignancy (including lymphoid malignancies such as chronic lymphocytic
             leukemia or low grade lymphoma) defined, in general, as requiring anticancer therapy
             or at high risk of recurrence during the study; not including adequately treated non
             melanomatous skin cancer or other solid tumors curatively treated with no evidence of
             disease in &gt; 3 years

          -  History of allergic reactions to therapeutic antisense oligonucleotides

          -  Active autoimmune disease requiring treatment

          -  Participated in a prior Phase 3 clinical study evaluating custirsen regardless of
             study arm assignment (i.e., either control or investigational arm), or prior exposure
             to OGX-427

          -  Uncontrolled medical conditions such as myocardial infarction, uncontrolled
             hypertension, stroke or treatment of a major active infection within 3 months of
             randomization, as well as any significant concurrent medical illness that in the
             opinion of the Investigator would preclude protocol therapy

          -  Planned concomitant participation in another clinical trial of an experimental agent,
             vaccine, or device. Concomitant participation in observational studies is acceptable.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Sweeney, M.B., B.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hoosier Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Sweeney, M.B., B.S.</last_name>
    <phone>617-632-4524</phone>
    <email>christopher_sweeney@dfci.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cynthia Burkhardt, R.N.</last_name>
    <phone>317-921-2050</phone>
    <email>cyburkha@iupui.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prostate Oncology Specialists, Inc.</name>
      <address>
        <city>Marina del Rey</city>
        <state>California</state>
        <zip>90292</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Scholz, M.D.</last_name>
      <email>mail@prostateoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Ken Chau</last_name>
      <phone>310.827.7707</phone>
      <phone_ext>32</phone_ext>
      <email>Ken@prostateoncology.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IU Health Bloomington Hospital</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Parsons, M.D.</last_name>
      <email>bparsons@bloomingtonhospital.org</email>
    </contact>
    <contact_backup>
      <last_name>Kim Hahn</last_name>
      <phone>812.353.5494</phone>
      <email>KHahn@bloomingtonhospital.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IU Health Goshen Hospital</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46527</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Starodub, M.D.</last_name>
      <phone>574-535-2886</phone>
      <email>astarodub@iuhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Eickhoff, R.N.</last_name>
      <phone>574.364.2649</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Costantine Albany, M.D.</last_name>
      <phone>317-278-1711</phone>
      <email>calbany@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kerry Bridges</last_name>
      <phone>317-274-2552</phone>
      <email>kdbridge@iupui.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IU Health Central Indiana Cancer Centers</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madelaine Sgroi, M.D.</last_name>
      <phone>317-859-5500</phone>
      <email>msgroi1@iuhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Cancer Research Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Taber, M.D.</last_name>
      <phone>574-234-5123</phone>
    </contact>
    <contact_backup>
      <last_name>Alicia Dombkowski</last_name>
      <phone>574-647-7390</phone>
      <email>adombkowski@beaconhealthsystem.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Sweeney, M.B., B.S.</last_name>
      <phone>617-632-4524</phone>
      <email>christopher_sweeney@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian Costello, M.D.</last_name>
      <phone>507-538-7623</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center: Albuquerque</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Laurer, M.D.</last_name>
      <email>rlaurer@salud.unm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathy Anderson</last_name>
      <phone>505-925-0405</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Fleming, M.D.</last_name>
      <phone>757-213-5813</phone>
      <email>mark.fleming@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Wendi Gobhart</last_name>
      <phone>757.213.5813</phone>
      <email>wendi.gobhart@usoncology.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Alberta Health Services: Cancer Care</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean Ruether, M.D.</last_name>
      <phone>403.521.3093</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott North, M.D.</last_name>
      <phone>780.432.8762</phone>
      <email>scottnor@cancerboard.ab.ca</email>
    </contact>
    <contact_backup>
      <last_name>Daphne Willan</last_name>
      <phone>780.432.8788</phone>
      <email>daphnewi@cancerboard.ab.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Chi, M.D.</last_name>
      <phone>604.877.6000</phone>
      <phone_ext>2737</phone_ext>
      <email>kchi@bccancer.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Shane Brown</last_name>
      <phone>604.877.6000</phone>
      <phone_ext>2370</phone_ext>
      <email>sbrown9@bccancer.bc.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Gingerich, M.D.</last_name>
      <email>joel.gingerich@cancercare.mb.ca</email>
    </contact>
    <contact_backup>
      <last_name>Heather Davies</last_name>
      <email>heather.davies@cancercare.mb.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Hotte, M.D.</last_name>
      <phone>905.387.9711</phone>
      <phone_ext>64605</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Diane Derosa</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fred Saad, M.D.</last_name>
      <phone>514.890.8000</phone>
      <phone_ext>27466</phone_ext>
      <email>fred.saad.chum@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sylvie Dagenais</last_name>
      <phone>514.890.8000</phone>
      <phone_ext>27466</phone_ext>
      <email>sylvie.dagenais.chum@ssss.gouv.qc.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.hoosieroncologygroup.org</url>
    <description>Hoosier Oncology Group Website</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>September 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OGX-427</keyword>
  <keyword>Abiraterone Acetate</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
